Hazel Park Primary Care LLC
Hazel Park Primary Care LLC was paid $6.46M by Medicaid between Apr 2020 and Dec 2024, across 49 billing codes. Its largest line is Q9992, Injection, buprenorphine extended-release (sublocade), greater than 100 mg — 29% of everything it billed.
33Billing provider infoHAZEL PARK PRIMARY CARE LLC
HAZEL PARK, MI 48030
HAZEL PARK, MI 48030
33aNPI1306407440assigned 06/27/2019
33bProvider typeChiropractor
28Total paid$6.46M
24GClaims67,229
24DCodes billed49
24AFirst – last monthApr 2020 – Dec 2024
Compared with peers
Next to other Chiropractor providers in Michigan
Rank by total paid#1 of 853
Median peer was paid$38K
This provider vs. median169×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,056 | $140K | |
| 2021 | 6,561 | $790K | |
| 2022 | 21,134 | $2.42M | |
| 2023 | 23,084 | $2.48M | |
| 2024incomplete | 14,394 | $631K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | 29% | 1,072 | 1,035 | $1.85M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 14% | 5,855 | 4,445 | $881K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 14,328 | 11,271 | $869K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 10,146 | 8,205 | $838K |
| J2315 | Injection, naltrexone, depot form, 1 mg | 12% | 581 | 557 | $766K |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | 7.2% | 260 | 246 | $464K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.6% | 8,863 | 6,941 | $359K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.4% | 1,523 | 1,409 | $154K |
| 80305 | 2.1% | 14,440 | 10,852 | $133K | |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | <1% | 902 | 838 | $43K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 556 | 523 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,524 | 3,079 | $16K |
37 more codes
| 99203 | Doctor's office visit, new patient (routine) | <1% | 208 | $15K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 134 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,592 | $6K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 131 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 170 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 90 | $2K |
| 99408 | <1% | 94 | $2K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 19 | $2K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14 | $1K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 14 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 32 | $1K |
| 99000 | <1% | 250 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 93 | $921.30 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 97 | $895.70 |
| 81002 | <1% | 314 | $701.78 | |
| 99218 | <1% | 12 | $700.72 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 25 | $595.98 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 12 | $474.52 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 29 | $419.38 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 12 | $310.16 |
| 99407 | <1% | 18 | $244.58 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $230.30 |
| 96127 | <1% | 99 | $217.10 | |
| 99406 | <1% | 46 | $189.86 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 35 | $62.57 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $48.60 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 29 | $33.24 |
| 97802 | <1% | 273 | $20.00 | |
| 3077F | 0% | 14 | $0.00 | |
| 99051 | 0% | 331 | $0.00 | |
| 3078F | 0% | 229 | $0.00 | |
| 3008F | 0% | 366 | $0.00 | |
| 3074F | 0% | 253 | $0.00 | |
| 99224 | 0% | 50 | $0.00 | |
| 3079F | 0% | 34 | $0.00 | |
| 3075F | 0% | 18 | $0.00 | |
| 1000F | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSALEH, MOHAMED (PRESIDENT)